Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Emerging immunotherapies for kidney cancer

Thomas Powles • 30 May 2015
ASCO 2015
Genitourinary Cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute, Queen Mary University of London, London, UK, provides an overview of promising novel immunotherapeutic strategies that are currently under investigation for the treatment of patients with kidney cancer.

More from Thomas Powles

2:04
Unmet educational needs in GU cancers
Thomas Powles • 16 Feb 2023
2:37
Key unmet needs in kidney cancer
Thomas Powles • 16 Feb 2023
1:44
Highlights in renal cell carcinoma from ASCO GU 2023 and what to look out for in the future
Thomas Powles • 23 Feb 2023
4:01
COSMIC-313: cabo + nivo + ipi in 1L advanced RCC of IMDC intermediate or poor risk
Thomas Powles • 16 Feb 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals